Daniel Delorme
Chief Tech/Sci/R&D Officer at Neurochem (International) Ltd.
Profile
Daniel Delorme is a professional with experience in the pharmaceutical industry.
He is currently the Vice President-Research at Neurochem (International) Ltd.
He previously held the position of Vice President-Research at BELLUS Health, Inc. and Vice President-Medicinal Chemistry at Mirati Therapeutics, Inc. He also served as Vice President-Research at Targanta Therapeutics, Inc. Dr. Delorme earned a doctorate degree from the University of Montréal.
Daniel Delorme active positions
| Companies | Position | Start |
|---|---|---|
Neurochem (International) Ltd.
 Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Chief Tech/Sci/R&D Officer | - |
Former positions of Daniel Delorme
| Companies | Position | End |
|---|---|---|
Targanta Therapeutics, Inc.
 Targanta Therapeutics, Inc. BiotechnologyHealth Technology Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada | Chief Tech/Sci/R&D Officer | 2004-12-31 |
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 2002-12-31 |
| BELLUS HEALTH | Chief Tech/Sci/R&D Officer | - |
Training of Daniel Delorme
| University of Montréal | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Commercial Services |
Targanta Therapeutics, Inc.
Targanta Therapeutics, Inc. BiotechnologyHealth Technology Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Daniel Delorme
